


Listing of Claims

1. - 77. (Canceled)

78. (Previously Presented) A method of inhibiting an activity of a GRP peptide, comprising: contacting the peptide with an effective amount of a pharmaceutical composition comprising a compound of formula XV, wherein formula XV is



and wherein

R₁ is: -R₅-(CH₂)_n-CH(R₆)OH, and R₅ is NH, S or O, R₆ is H or CH₃; and n is an integer from 1-4;


R₂ is NH₂, substituted amino or acetamide;

R₃ is H, halogen, CH₃, or CF₃; and

R₄ is H, alkyl, substituted alkyl, alkenyl, alkoxy or halogen.


79. (Previously Presented) The method of claim 78, wherein the GRP activity is stimulating intracellular levels of one or both of IP₃ or Ca⁺².

80. (Previously Presented) The method of claim 78, wherein the pharmaceutical composition is a compound of formula XV', wherein XV' is:



81. (Previously Presented) The method of claim 80, wherein the GRP activity is stimulating intracellular levels of one or both of IP₃ or Ca⁺².

82. (Previously Presented) A method of treating a condition by inhibiting an activity of GRP, comprising: administering to a patient in need of such treatment an effective amount of a pharmaceutical composition comprising a compound of formula XV, wherein formula XV is



and wherein

R₁ is: -R₅-(CH₂)_n-CH(R₆)OH, and R₅ is NH, S or O, R₆ is H or CH₃; and n is an integer from 1-4;

R₂ is NH₂, substituted amino or acetamide;

R₃ is H, halogen, CH₃, or CF₃; and

R₄ is H, alkyl, substituted alkyl, alkenyl, alkoxy or halogen.

83. (Previously Presented) The method of claim 82, wherein the condition is hypotension, an eating disorder, or bronchopulmonary dysplasia.

84. (Previously Presented) The method of claim 82, wherein the condition is mediated by aberrant angiogenesis.

85. (Previously Presented) The method of claim 84, wherein the condition is selected from the group consisting of: arthritis, psoriasis, benign growths caused by rapidly dividing cells, brain ischaemia, atherosclerosis, myocardial angiogenesis, post-balloon angioplasty, vascular restenosis, neointima formation following vascular trauma, vascular graft restenosis, coronary collateral formation, deep venous thrombosis, ischemic limb angiogenesis, diabetic neovascularization, neovascular glaucoma, macular degeneration, diabetic and other retinopathy, retrolental fibroplasias, corneal diseases, fibrosis, deep venous thrombosis, endometriosis, and wrinkles.


86. (Previously Presented) The method of claim 84, wherein the condition is a cellular proliferative disease.

87. (Previously Presented) The method of claim 86, wherein the cellular proliferative disease is a sarcoma, carcinoma, lymphoma, malignant melanoma, or benign growth caused by rapidly dividing cells.

88. (Previously Presented) The method of claim 86, wherein the cellular proliferative disease is a primary tumor growth, tumor invasion, metastasis, or two or more thereof.

89. (Previously Presented) The method of claim 86, wherein the cellular proliferative disease is a cancer selected from the group consisting of: adrenal, glioma, astrocytoma, neuroblastoma, renal, lung, pancreatic, gastric, gastrointestinal, lung, colon, colorectal, prostate, ovarian, breast, and chondrosarcoma.

90. (Previously Presented) The method of claim 82, wherein the pharmaceutical composition is a compound of formula XV', wherein XV' is:



91. (Previously Presented) The method of claim 90, wherein the condition is hypotension, an eating disorder, or bronchopulmonary dysplasia.

92. (Previously Presented) The method of claim 90, wherein the condition is mediated by aberrant angiogenesis.

93. (Previously Presented) The method of claim 92, wherein the condition is selected from the group consisting of: arthritis, psoriasis, benign growths caused by rapidly dividing cells, brain ischaemia, atherosclerosis, myocardial angiogenesis, post-balloon angioplasty, vascular restenosis, neointima formation following vascular trauma, vascular graft restenosis, coronary

collateral formation, deep venous thrombosis, ischemic limb angiogenesis, diabetic neovascularization, neovascular glaucoma, macular degeneration, diabetic and other retinopathy, retrolental fibroplasias, corneal diseases, fibrosis, deep venous thrombosis, endometriosis, and wrinkles.

94. (Previously Presented) The method of claim 92, wherein the condition is a cellular proliferative disease.

95. (Previously Presented) The method of claim 94, wherein the cellular proliferative disease is a sarcoma, carcinoma, lymphoma, malignant melanoma, or benign growth caused by rapidly dividing cells.

96. (Previously Presented) The method of claim 94, wherein the cellular proliferative disease is a primary tumor growth, tumor invasion, metastasis, or two or more thereof.

97. (Previously Presented) The method of claim 94, wherein the cellular proliferative disease is a cancer selected from the group consisting of: adrenal, glioma, astrocytoma, neuroblastoma, renal, lung, pancreatic, gastric, gastrointestinal, lung, colon, colorectal, prostate, ovarian, breast, and chondrosarcoma.

98. (Previously Presented) A kit for carrying out the method of claim 82 comprising: a pharmaceutical composition comprising a compound of formula XV and instructions for carrying out the method.

99. (Previously Presented) The kit of claim 98, wherein the pharmaceutical composition is a compound of formula XV', wherein XV' is:

